0001209191-18-039545.txt : 20180626 0001209191-18-039545.hdr.sgml : 20180626 20180626200022 ACCESSION NUMBER: 0001209191-18-039545 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20180626 FILED AS OF DATE: 20180626 DATE AS OF CHANGE: 20180626 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Access Industries Holdings LLC CENTRAL INDEX KEY: 0001391297 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38551 FILM NUMBER: 18920315 BUSINESS ADDRESS: STREET 1: C/O ACCESS INDUSTRIES MANAGEMENT, LLC. STREET 2: 730 FIFTH AVENUE, 20TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10019 BUSINESS PHONE: 212 247 6400 MAIL ADDRESS: STREET 1: C/O ACCESS INDUSTRIES MANAGEMENT, LLC. STREET 2: 730 FIFTH AVENUE, 20TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10019 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Clal Biotechnology Industries Ltd. CENTRAL INDEX KEY: 0001468950 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38551 FILM NUMBER: 18920316 BUSINESS ADDRESS: STREET 1: 3AZRIELI CENTER TRIANGLE TOWER 45 FLOOR CITY: TEL AVIV STATE: L3 ZIP: 67023 BUSINESS PHONE: 972-3-6075794 MAIL ADDRESS: STREET 1: 3AZRIELI CENTER TRIANGLE TOWER 45 FLOOR CITY: TEL AVIV STATE: L3 ZIP: 67023 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ACCESS INDUSTRIES, LLC CENTRAL INDEX KEY: 0001508227 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38551 FILM NUMBER: 18920317 BUSINESS ADDRESS: STREET 1: 730 FIFTH AVENUE CITY: NEW YORK STATE: NY ZIP: 10019 BUSINESS PHONE: 2122476400 MAIL ADDRESS: STREET 1: 730 FIFTH AVENUE CITY: NEW YORK STATE: NY ZIP: 10019 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ACCESS INDUSTRIES MANAGEMENT, LLC CENTRAL INDEX KEY: 0001508226 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38551 FILM NUMBER: 18920318 BUSINESS ADDRESS: STREET 1: 730 FIFTH AVENUE CITY: NEW YORK STATE: NY ZIP: 10019 BUSINESS PHONE: 2122476400 MAIL ADDRESS: STREET 1: 730 FIFTH AVENUE CITY: NEW YORK STATE: NY ZIP: 10019 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Blavatnik Len CENTRAL INDEX KEY: 0001326628 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38551 FILM NUMBER: 18920319 MAIL ADDRESS: STREET 1: C/O ACCESS INDUSTRIES STREET 2: 730 FIFTH AVENUE CITY: NEW YORK STATE: NY ZIP: 10019 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Neon Therapeutics, Inc. CENTRAL INDEX KEY: 0001694187 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 40 ERIE STREET STREET 2: SUITE 110 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-337-4701 MAIL ADDRESS: STREET 1: 40 ERIE STREET STREET 2: SUITE 110 CITY: CAMBRIDGE STATE: MA ZIP: 02139 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2018-06-26 0 0001694187 Neon Therapeutics, Inc. NTGN 0001391297 Access Industries Holdings LLC C/O ACCESS INDUSTRIES, INC. 40 WEST 57TH STREET, 28TH FLOOR NEW YORK NY 10019 0 0 1 0 0001468950 Clal Biotechnology Industries Ltd. 3 AZRIELI CENTER TRIANGLE TOWER 45 FLOOR TEL AVIV L3 67023 ISRAEL 0 0 1 0 0001508227 ACCESS INDUSTRIES, LLC C/O ACCESS INDUSTRIES, INC. 40 WEST 57TH STREET, 28TH FLOOR NEW YORK NY 10019 0 0 0 1 Affiliate of 10% Owner 0001508226 ACCESS INDUSTRIES MANAGEMENT, LLC C/O ACCESS INDUSTRIES, INC. 40 WEST 57TH STREET, 28TH FLOOR NEW YORK NY 10019 0 0 0 1 Affiliate of 10% Owner 0001326628 Blavatnik Len C/O ACCESS INDUSTRIES, INC. 40 WEST 57TH STREET, 28TH FLOOR NEW YORK NY 10019 0 0 0 1 Affiliate of 10% Owner Series A Preferred Stock Common Stock 999998 D Series A Preferred Stock Common Stock 999998 D Series B Preferred Stock Common Stock 782917 D Each share of Series A Preferred Stock is currently convertible into shares of the Issuer's common stock, $0.001 par value per share ("Common Stock") on approximately a 5:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock will convert into shares of Common Stock of the Issuer. The Series A Preferred Stock has no expiration date. The securities reported are held directly by Access Industries Holdings LLC ("AIH") and may be deemed to be beneficially owned by Access Industries, LLC ("Access LLC"), Access Industries Management, LLC ("Management LLC") and Len Blavatnik, because Access LLC holds a majority of the outstanding voting interests in AIH, Management LLC controls Access LLC and AIH, and Len Blavatnik controls Management LLC and Access LLC. Each of the reporting persons (other than AIH) disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, if any, and this Form shall not be construed as an admission that any such reporting person is the beneficial owner of such securities for any purpose. The securities reported are held directly by Clal Biotechnology Industries Ltd. ("CBI"). AIH, Access LLC, Management LLC and Len Blavatnik may be deemed to beneficially own the securities held directly by CBI because Clal Industries Ltd. ("CI") is the controlling shareholder of CBI, AIH controls CI, Access LLC holds a majority of the outstanding interests in AIH, Management LLC controls Access LLC, and Len Blavatnik controls Management LLC and Access LLC. Each of the reporting persons, other than CBI, disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, if any, and this Form shall not be construed as an admission that any such reporting person (other than CBI) is the beneficial owner of such securities for any purpose. Each share of Series B Preferred Stock is currently convertible into shares of the Issuer's Common Stock on approximately a 5:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series B Preferred Stock will convert into shares of Common Stock of the Issuer. The Series B Preferred Stock has no expiration date. Exhibit List Ex.24 - Power of Attorney /s/ Alejandro Moreno for Access Industries Holdings LLC 2018-06-26 /s/ Ofer Gonen (CEO) and Assaf Segal (CFO) for Clal Biotechnology Industries Ltd. 2018-06-26 /s/ Alejandro Moreno for Access Industries, LLC 2018-06-26 /s/ Alejandro Moreno for Access Industries Management, LLC 2018-06-26 /s/ Alejandro Moreno, as Attorney-in-Fact for Mr. Blavatnik 2018-06-26 EX-24 2 attachment1.htm EX-24 DOCUMENT

LIMTED POWER OF ATTORNEY


Know all by these presents, that the undersigned hereby constitutes and appoints
Lincoln Benet and Alejandro Moreno, and each of them individually, the
undersigned's true and lawful attorney-in-fact to:
	execute for and on behalf of the undersigned, in the undersigned's capacity as
a beneficial owner of Neon Therapeutics, Inc. (the "Company"): (i) Forms 3, 4
and 5 and any other forms required to be filed in accordance with Section 16(a)
of the Securities Exchange Act of 1934 (the "Exchange Act") and the rules
thereunder (a "Section 16 Form"), (ii) all forms and schedules in accordance
with Section 13(d) of the Exchange Act and the rules thereunder, including all
amendments thereto (a "Section 13 Schedule"), (iii) a Form ID Application,
Passphrase Update Application and/or request to convert from paper only to
electronic filer with the U.S. Securities and Exchange Commission and to obtain
access codes to file on EDGAR and any other forms required to be filed or
submitted in accordance with Regulation S-T promulgated by the United States
Securities and Exchange Commission (or any successor provision) in order to file
a Section 13 Schedule or a Section 16 Form electronically (a "Form ID", and,
together with a Section 16 Form and a Section 13 Schedule, the "Forms and
Schedules") and (iv) any Joint Filing Agreement or similar agreement with
respect to the filing of any of the Forms or Schedules in (i) through (iii)
above;
	do and perform any and all acts for and on behalf of the undersigned which may
be necessary or desirable to complete and execute any such Forms and Schedules,
complete and execute any amendments thereto, and timely file such Forms and
Schedules with the U.S. Securities and Exchange Commission and any stock
exchange or similar authority; and
	take any other action of any type whatsoever in connection with the foregoing
which, in the opinion of each such attorney-in-fact, may be of benefit to, in
the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by each such attorney-in-fact on behalf
of the undersigned pursuant to this Limited Power of Attorney shall be in such
form and shall contain such terms and conditions as he may approve in his
discretion.
The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that each such attorney-in-fact, or his
substitute or substitutes, shall lawfully do or cause to be done by virtue of
this Limited Power of Attorney and the rights and powers herein granted.
The undersigned acknowledges that each such attorney-in-fact is serving in such
capacity at the request of the undersigned, and is not assuming, nor is the
Company assuming, any of the undersigned's responsibilities to comply with
Section 13 or Section 16 of the Exchange Act.
This Limited Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file any Forms and Schedules with respect
to the undersigned's holdings of and transactions in securities issued by the
Company, unless earlier revoked by the undersigned in a signed writing delivered
to each such attorney-in-fact.
From and after the date hereof, any Limited Power of Attorney previously granted
by the undersigned concerning the subject matter hereof is hereby revoked.
IN WITNESS WHEREOF, the undersigned has executed this Limited Power of Attorney
as of June 20, 2018.
LEONARD BLAVATNIK


/s/ Leonard Blavatnik